T
TREVI THERAPEUTICS INC
NASDAQ: TRVI (Trevi Therapeutics, Inc.)
Last update: 3 hours ago5.95
0.00 (0.00%)
| Previous Close | 5.95 |
| Open | 5.90 |
| Volume | 1,157,793 |
| Avg. Volume (3M) | 1,769,425 |
| Market Cap | 724,442,240 |
| Price / Book | 7.28 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -0.450 |
| Total Debt/Equity (MRQ) | 0.96% |
| Current Ratio (MRQ) | 15.38 |
| Operating Cash Flow (TTM) | -41.27 M |
| Levered Free Cash Flow (TTM) | -24.53 M |
| Return on Assets (TTM) | -34.41% |
| Return on Equity (TTM) | -55.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Trevi Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 75.65% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Cantor Fitzgerald, 320.17%) | Buy |
| Median | 22.50 (278.15%) | |
| Low | 21.00 (HC Wainwright & Co., 252.94%) | Buy |
| 21.00 (D. Boral Capital, 252.94%) | Buy | |
| Average | 22.75 (282.35%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 6.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 01 Jul 2025 | 25.00 (320.17%) | Buy | 5.70 |
| D. Boral Capital | 02 Jun 2025 | 21.00 (252.94%) | Buy | 6.32 |
| HC Wainwright & Co. | 28 May 2025 | 21.00 (252.94%) | Buy | 6.26 |
| Needham | 20 May 2025 | 24.00 (303.36%) | Buy | 6.47 |
| 08 Apr 2025 | 24.00 (303.36%) | Buy | 5.30 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |